<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703157</url>
  </required_header>
  <id_info>
    <org_study_id>BRC-CS</org_study_id>
    <nct_id>NCT00703157</nct_id>
  </id_info>
  <brief_title>Surgical or Catheter Ablation of Lone Atrial Fibrillation (AF) Patients</brief_title>
  <acronym>SCALAF</acronym>
  <official_title>Surgical or Catheter Ablations in Patients With Lone Atrial Fibrillation: Determination of Acute and Long Term Success Rate (SCALAF Success Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized interventional trial comparing the efficacy of circumferential
      pulmonary vein ostia ablation using surgical versus catheter techniques in the treatment of
      paroxysmal atrial fibrillation. Success rate determined by REVEAL-XT (AF implantable
      monitoring device).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Surgical or Catheter Ablation in patients with Lone Atrial Fibrillation: determination
      of acute and long term SUCCESS (SCALAF-success trial).

      Background: Anti-arrhythmic drugs are used in daily practice to treat patients with
      paroxysmal idiopatic AF. Often the origin of the AF can be found in the muscle sleeves
      running up the pulmonary veins. Drug treatment is not always successful and prone to evoke
      negative side effects. The surgical MAZE procedure was applied in the past, but this is a
      time consuming, cumbersome technique, often associated with significant complications.
      Cardiac radio-frequency ablation offers an alternative, easy and less time consuming
      treatment: lesions prevent normal electrical wave front propagation and might stop the
      continuation of atrial fibrillation wave fronts. Ablation can be implemented by use of
      special catheters inserted via the groin or using the Medtronic CardioblateÂ® Surgical
      Ablation System applied via minimal invasive surgical techniques.

      Purpose: Compare the effectiveness of pulmonary vein isolation achieved via catheter or via
      surgical ablation techniques to treat patients with paroxysmal lone AF.

      Study design: A prospective, randomized multi-center interventional study.

      Patients: Patients suffering from paroxysmal idiopatic AF (no associated or underlying
      structural heart disease) complying with following inclusion criteria:

        -  minimally one documented AF-episode in the last 6 months;

        -  refractory to at least 2 class I or III anti-arrhythmic drugs;

        -  age &gt; 18 year

      Intervention: Patients are randomized to either the surgical or the catheter ablation group
      and receive the indicated treatment. During the critical assessment period, the patients are
      weaned from anti-arrhythmic medication.

      Primary endpoint: Reduction in AF occurrence measured by the AF-burden parameter in the
      critical period between 3 and 6 months post-ablation. AF burden is measured automatically by
      means of the Reveal XT, implanted at study enrolment to document the baseline
      characteristics.

      Secondary endpoints:

        -  Failure of therapy requiring re-interventions;

        -  Duration, burden and costs of ablation procedures:

        -  Reduction in frequency, duration and level of severity of AF symptoms;

        -  Occurences of treatments of arrythmic episodes;

        -  Assessment of AF burden during follow-up period

        -  Symptoms associated with AF;

        -  Reduced necessity of anti-arrhythmic or anticoagulant medication;

        -  Left atrial dimensions and contractility

        -  Adverse events associated with the ablation therapy;

        -  Occurrence of other clinical adverse events (TIA, CVA, bleeds, tamponade, MI) at 3, 6,
           12 and 24 months of follow up

        -  Mortality and hospitalisation

      Risk assessment: Possible side effects : irregular heart rhythm, pericardial fluid, stroke,
      heart infarct, disturbances of the conduction system in the heart, local pain at the site of
      incisions, heart failure or reduced pump function of the heart.

      Possible benefits: Regulation of the heart rhythm without applying MAZE procedure or opening
      of the thorax. Reduction or relief from symptoms associated with AF. Partial or complete
      reduction of anti-arrhythmic medication. Control of anti-coagulant medication. Improved
      quality of life for the patients.

      Visits are planned at study entrance and Reveal XT implant (assessment at baseline,
      application of the ablation therapy), discharge from hospital, and at 3, 6, 12 and 24 months
      post-ablation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollments slowed down significantly, despite several attempts to re-launch.
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in AF Burden After Ablation Therapy Measured With REVEAL-XT Implantable Device.</measure>
    <time_frame>Baseline through 3-6 months post-ablation</time_frame>
    <description>AF Burden is defined as the percentage of time during the follow-up period that a subject is in AF, as measured by the REVEAL-XT implantable device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Failures Requiring Redo or Alternative Therapy</measure>
    <time_frame>Time from procedure until 6 months post-ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events, Associated With the Ablation Procedure</measure>
    <time_frame>Time from procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality and Hospitalization</measure>
    <time_frame>Time from procedure until 24 months post-ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration, Burden and Costs of Treatment Procedures</measure>
    <time_frame>Through 24 months post- ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced Number, Duration and Severity of AF Symptoms</measure>
    <time_frame>Through 24 months post-ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms Associated With Atrial Arrhythmias</measure>
    <time_frame>Through 24 months post-ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurences of Treatment of Arrhythmic Episodes</measure>
    <time_frame>Through 24 months post-ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of AF Burden</measure>
    <time_frame>Through 24 months post-ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced Anti-arrhythmic Drug Requirement</measure>
    <time_frame>Through 24 months post-ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Atrial Dimension and Contractility</measure>
    <time_frame>Through 24 months post-ablation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: Catheter Ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: Surgical Ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter Ablation</intervention_name>
    <description>Patients undergoing left atrial circumferential pulmonary vein ostia ablation.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Ablation</intervention_name>
    <description>patients undergoing left atrial circumferential pulmonary vein ostia ablation via minimal invasive surgery.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has documented Paroxysmal AF as defined by the ACC/AHA/ESC guidelines

          -  Minimal one documented AF episode in the last 6 months

          -  Refractory to minimal two Class I or III anti-arrhythmic drug

          -  Age &gt; 18 years

          -  Signed and dated the Patient Informed Consent.

          -  Patient can tolerate anti-coagulation therapy (Warfarin/Coumadin)

        Exclusion Criteria:

          -  Patient has a structural heart disease

          -  Ejection fraction &lt; 40 %

          -  Echocardiographic evidence for a left atrium &gt; 45 mm (parasternal axis)

          -  Patients on amiodarone, or patients known to be intolerant for amiodarone

          -  Dextrocardia, current endocarditis, systemic infection, renal failure

          -  Patient has known cerebrovascular disease, including a history of stroke, CVA or TIA

          -  Pregnancy at enrolment; or planned pregnancy within the follow up period

          -  Patient has a life expectancy less than 1 year

          -  The subject is participating in another device or drug study

          -  The patient is unable and/or unwilling to cooperate with study procedures or required
             follow up visits

          -  Echocardiographic (TTE) evidence for presence of left atrial thrombus

          -  Previous (cardio-) thoracic surgery

          -  Previous left atrial ablation

          -  Patients with permanent or persistent AF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hauw Sie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isala Klinieken, Zwolle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <results_first_submitted>March 22, 2017</results_first_submitted>
  <results_first_submitted_qc>May 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 16, 2017</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan or intention to share individual participant data (IPD)</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eighty (80) subjects were enrolled, of whom 52 were randomized. A Reveal XT Implantable device was implanted in all subjects after Informed Consent. The subjects were followed for a minimum of 1 week and a maximum of 6 months. If the subject demonstrated a minimum of 10% AF burden during this period and had complaints, the subject was randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Catheter</title>
          <description>Catheter Ablation</description>
        </group>
        <group group_id="P2">
          <title>Surgery</title>
          <description>Surgical Ablation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Months FU</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>24 Months FU</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>source data permanently lost/ other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Catheter</title>
          <description>Catheter Ablation</description>
        </group>
        <group group_id="B2">
          <title>Surgery</title>
          <description>Surgical Ablation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="7"/>
                    <measurement group_id="B2" value="55" spread="9"/>
                    <measurement group_id="B3" value="58" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Class</title>
          <description>The New York Heart Association (NYHA) Functional Classification places patients in one of four categories based on their limitations during physical activity.The limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina.
Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in AF Burden After Ablation Therapy Measured With REVEAL-XT Implantable Device.</title>
        <description>AF Burden is defined as the percentage of time during the follow-up period that a subject is in AF, as measured by the REVEAL-XT implantable device.</description>
        <time_frame>Baseline through 3-6 months post-ablation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Catheter</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Surgical Ablation</description>
          </group>
          <group group_id="O3">
            <title>All Subjects</title>
            <description>All Subjects, regardless of randomization group</description>
          </group>
        </group_list>
        <measure>
          <title>Change in AF Burden After Ablation Therapy Measured With REVEAL-XT Implantable Device.</title>
          <description>AF Burden is defined as the percentage of time during the follow-up period that a subject is in AF, as measured by the REVEAL-XT implantable device.</description>
          <units>percentage of time in AF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-ablation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="7.4"/>
                    <measurement group_id="O2" value="7.9" spread="8.7"/>
                    <measurement group_id="O3" value="7.8" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blanking Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="4.2"/>
                    <measurement group_id="O2" value="3.6" spread="6.1"/>
                    <measurement group_id="O3" value="2.6" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Change Pre to Blanking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="6.1"/>
                    <measurement group_id="O2" value="-4.3" spread="7.2"/>
                    <measurement group_id="O3" value="-5.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Ablation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.4"/>
                    <measurement group_id="O2" value="2.0" spread="5.5"/>
                    <measurement group_id="O3" value="1.3" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Change Blanking to Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="3.2"/>
                    <measurement group_id="O2" value="-1.1" spread="5.5"/>
                    <measurement group_id="O3" value="-1.3" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change Pre to Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.8" spread="68.4"/>
                    <measurement group_id="O2" value="-70.8" spread="65.1"/>
                    <measurement group_id="O3" value="-74.2" spread="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Change Pre to Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="7.1"/>
                    <measurement group_id="O2" value="-5.8" spread="9.1"/>
                    <measurement group_id="O3" value="-6.5" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Failures Requiring Redo or Alternative Therapy</title>
        <time_frame>Time from procedure until 6 months post-ablation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Catheter</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Surgical Ablation</description>
          </group>
          <group group_id="O3">
            <title>All Subjects</title>
            <description>All Subjects, regardless of randomization group</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failures Requiring Redo or Alternative Therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events, Associated With the Ablation Procedure</title>
        <time_frame>Time from procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Catheter</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Surgical Ablation</description>
          </group>
          <group group_id="O3">
            <title>All Subjects</title>
            <description>All Subjects, regardless of randomization group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events, Associated With the Ablation Procedure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality and Hospitalization</title>
        <time_frame>Time from procedure until 24 months post-ablation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Catheter</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Surgical Ablation</description>
          </group>
          <group group_id="O3">
            <title>All Subjects</title>
            <description>All Subjects, regardless of randomization group</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality and Hospitalization</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Procedure-Related Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration, Burden and Costs of Treatment Procedures</title>
        <time_frame>Through 24 months post- ablation</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Surgical Ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Duration, Burden and Costs of Treatment Procedures</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduced Number, Duration and Severity of AF Symptoms</title>
        <time_frame>Through 24 months post-ablation</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Surgical Ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Reduced Number, Duration and Severity of AF Symptoms</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms Associated With Atrial Arrhythmias</title>
        <time_frame>Through 24 months post-ablation</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Surgical Ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms Associated With Atrial Arrhythmias</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurences of Treatment of Arrhythmic Episodes</title>
        <time_frame>Through 24 months post-ablation</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Surgical Ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Occurences of Treatment of Arrhythmic Episodes</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of AF Burden</title>
        <time_frame>Through 24 months post-ablation</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Surgical Ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of AF Burden</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduced Anti-arrhythmic Drug Requirement</title>
        <time_frame>Through 24 months post-ablation</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Surgical Ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Reduced Anti-arrhythmic Drug Requirement</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Atrial Dimension and Contractility</title>
        <time_frame>Through 24 months post-ablation</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Surgical Ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Left Atrial Dimension and Contractility</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Adverse Events were monitored for a limited timeframe, ie.up to 6 Months Post-Ablation, by Randomization Group</desc>
      <group_list>
        <group group_id="E1">
          <title>Catheter</title>
          <description>Catheter Ablation</description>
        </group>
        <group group_id="E2">
          <title>Surgery</title>
          <description>Surgical Ablation</description>
        </group>
        <group group_id="E3">
          <title>All Randomized Subjects</title>
          <description>All Randomized Subjects, regardless of randomization group</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness transient</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebralvascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Parapalegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>External Cephalic Version</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cardiac ablation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sternotomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study stopped early, prior to meeting the target number of subjects per group. The reported results and conclusions are based on these limited data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ber Kleijnen</name_or_title>
      <organization>Medtronic Bakken Research Center, Coronary and Structural Heart Disease Management</organization>
      <phone>+31 (0) 43 356 6566</phone>
      <email>ber.kleijnen@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

